2
Investors
About
LumiraDx develops rapid, automated microfluidic immunofluorescence diagnostic testing platforms for near-patient testing, including rapid detection of SARS-CoV-2 antigen from nasal and nasopharyngeal swabs.
Explore LumiraDx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.